Prenetics Global Ltd (PRE): רווח למניה בשנים עשר החודשים האחרונים

Prenetics Global leads in precision diagnostics by investing in AI-driven DNA analysis and portable tests. The trend of the rolling annual earnings per share illustrates financial resilience, where the -4.17 parameter determines the metric's magnitude. Stable demand for genetics from clinics supports cash flow and operational growth. Efficiency is achieved by outsourcing production and IT infrastructure to external contract partners.

To identify objective yield benchmarks, investors analyze the annual net income per share, which isolates financial results from the impact of issuance volume. The TTM fundamental net income per share trend confirms the effectiveness of the Prenetics Global (PRE) business model, where high margins from genomic testing and corporate contracts translate into sustainable profit growth and high-quality free cash flow.